Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Department of Philosophy | McMaster University
1280 Main Street West | Hamilton, Ontario L8S 4k1
Ethical Considerations for
Human Challenge Studies
Claudia I. Emerson, Ph.D.
Accelerating vaccine development in the UK Safely: enhancing
Human Challenges Studies to combat infectious diseases
The Academy of Medical Sciences, London, UK
6 February 2018
Institute on Ethics & Policy for Innovation
Consider
2
• Human challenge studies are different from other non-therapeutic research
• It is difficult for current ethical guidelines to justify challenge studies → primum non nocere
Institute on Ethics & Policy for Innovation
Consider further
• Human challenge studies date back to the 18th century
• 22,000 volunteers have participated in well-regulated human challenges studies in the last 70 years
• Nearly 60 different challenge strains used in studies for vector borne, respiratory and enteric diseases
• Human challenge studies have played a pivotal role in the development of vaccines (e.g. cholera, typhoid), including providing the primary evidence of effectiveness for a new cholera vaccine licensed in the US (Vaxchora).
[Gordon et al, 2017]
3
Institute on Ethics & Policy for Innovation
Significant policy gaps
• Policy gaps and variation in the regulatory environment
“In the UK, there are few guidelines for setting up new human challenge studies and a more structured pathway would be useful.”
“human challenge studies have a more complex regulatory requirement in the US than the European Union, including the UK”
“The reasons why human challenges studies are not carried out in Low and Middle Income Countries (LMIC) include technical, clinical, ethical and regulatory issues, as well as cultural norms.”
[Gordon et al, 2017]
• Ethics committees have little guidance to conduct evaluation of human challenge studies, e.g. assessment of risk and benefit
4
Institute on Ethics & Policy for Innovation
Gaps in ethics guidance
• From the report (2017) Ethical Considerations for Zika Virus Human
Challenge Trials:
5
• “the literature provides limited guidance on the ethics of
conducting challenge studies when the medical consequences of
infection are more uncertain.”
• “the ethics literature provides very little specificity on the
reasonable limits on the net risk to research volunteers”
• “the question of how to address risks to third parties is unsettled
in prior literature”
Institute on Ethics & Policy for Innovation
On risk
• Risk (even elevated risk) does not make a study unethical
• What is the acceptable threshold for risk?
o Minimal risk (Hope & McMillan, 2004)
o Risk assumed by volunteer firefighters (London, 2007)
o Risk assumed by kidney donors (Miller and Joffe, 2009)
o Risk greater than 1% chance of death, permanent disability or severe injury (Resnick, 2012)
o Risk cannot be so great as to expose volunteers to irreversible, incurable or possible fatal infections (Bamberry et al, 2016)
• In the absence of challenge studies, more people would be
placed at risk of exposure to ineffective vaccines and potentially
harmed → challenge studies might be ethically required, and not
merely ethically permissible (Bamberry et al, 2016)
6
Institute on Ethics & Policy for Innovation
On justification, and risk/benefit balance
• Greater ethical justification, and risk/benefit balance to conduct
human challenge studies in disease endemic settings
o Comparative risk of participation is lower than non-endemic settings
o Research is relevant to the local community
o Provision of optimal care in controlled environment
o Subsequent immunity to wild-type infection (in case of challenge studies
testing vaccines)
o Build local capacity: in clinical facilities; laboratory diagnostics; experimental
medicine; clinical governance and regulatory confidence
o Accelerate or streamline vaccine/treatment relevant to the national health
burden
7
Institute on Ethics & Policy for Innovation
Registered human challenge studies on clinicaltrials.gov
155 Trials
76 Malaria
30 Influenza
12 RSV
9 Norovirus
6 Shigella
5 Typhoid
4 Campylobacter
4 TB
2 Hookworm
1 Cholera, Common Cold,
Dengue, E. Coli,
Pneumococcal,
Schistosomiasis, Celiac
Disease
8
49%
19%
7%
6%
4%
3%
challenge study by disease
Malaria Influenza RSV Norovirus
Shigella Typhoid Campylobacter TB
Hookworm Cholera Common cold Dengue
E. Coli Pneumococcal Schistosomiasis Celiac Disease
Institute on Ethics & Policy for Innovation
Where are human challenges studies conducted?
• In a sample of 155 human challenges studies registered on
clinicaltrials.gov: 12 (~7%) were located in an LMIC
9
61
53
17
5 4 2 1 1 2 1 1 3 1 3
# R
EG
ISTERED
COUNTRY
CHIM TRIALS ACCORDING TO LOCATION*
*Includes completed, active and not yet recruiting
studies
Institute on Ethics & Policy for Innovation
Challenges of conducting human challenge studies in LMICs
PRACTICAL ETHICAL
Infrastructure and clinical facilities may
not be ready, specifically to monitor and
support adverse events (e.g. on intensive
care units)
Fair recruitment and inclusion of healthy
volunteers
Poor community hygiene and sanitation
infrastructure could prevent effective
control measures
Inherent vulnerabilities may impact fully
informed consent in the local context
(e.g. language, cultural family/group
consent)
Production of challenge strain locally
may have QA issues but “international”
strains may be less relevant
Consensus on appropriate compensation
for monetary and opportunity costs is
lacking
10
[Gordon et al, 2017]
Institute on Ethics & Policy for Innovation
Expanded framework for ethical evaluation of human
challenge studies
11
Ethical Issue Sample questions and considerations
1. Rationale for CHIM • What is the justification for using infection-inducing challenge model?
• Have alternative methods been considered?
2. Risks • Is there possibility of serious risk or harm?
• Are there potential risks of transmission to others?
3. Discomforts • How will discomforts be minimized?
4. Vulnerable subjects • How will vulnerability be assessed?
5. Informed consent • Is there adequate information about purpose, procedures, (including isolation, if relevant),
risks, discomforts, lack of benefit?
6. Financial compensation • Is it commensurate with the time and effort required?
• Does it constitute undue inducement?
7. Right to withdraw from research • Is the time and method of isolation limited to that necessary to protect others?
(Miller & Grady, 2001)
8. Independent review • If new challenge model, has it been reviewed and approved by 2 independent experts in
infectious diseases?
9. Publicly available rationale • Has a clear publicly accessible rationale for the study been made available, explaining the
nature of the benefits and risks, the inadequacy of alternatives, and the adequacy of the
measures to protect participants and the community from harm?
10. Protection of the public • Are there measures in place to protect the community from spread outside the research
setting?
11. New model of compensation for
harm
• Compensation for risk (ex ante) versus compensation for harm (ex poste)
(Bamberry et al, 2016)
Institute on Ethics & Policy for Innovation
Data gap
12
• “Estimates of severe complication rates from FDA-regulated first-in-
human trials are not available”
• “Many of the published influenza challenge studies, however, did
not indicate whether adverse events occurred.”
• “it is also unclear whether the data about the risks to volunteers in
human challenge studies are comprehensive”
• “ A key aim is to share data and information gained, aggregating
data from multiple studies to enhance the information and
interpretation.”
[Shah et al, 2017; Sheets et al, 2016]
Institute on Ethics & Policy for Innovation
Further expansion of the expanded framework for ethical
evaluation of human challenge studies*
Ethical Issue Sample Considerations
12. Knowledge and Data
Sharing
• To promote collaboration and strengthen capacity (scientific,
regulatory, ethics), mitigate risks and increase benefits
• Build a ‘community of practice’, and develop best practices
13. Community
Engagement**
• A critical adjunct to the informed consent process
• Essential for trust building: participant communities, public, policy and
decision-makers (**Zika Virus Human Challenge Research Writing Committee, 2017)
14. Governance • SOPs, Standardized Materials, and Principles to set standards in the
field to promote high scientific and ethical practices
13
[*Emerson & Cullen, unpublished manuscript, 2018]
Institute on Ethics & Policy for Innovation
Building a ‘Community of Practice’
14
Guiding Principles for Funders and Supporters of Human Challenge
Studies (forthcoming 2018)
Institute on Ethics & Policy for Innovation
Acknowledgments
15
Katelyn Cullen, MPH